VivoSeq
Oncology

AIDS-Related Diffuse Large B-Cell Lymphoma

8

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

AIDS-Related Diffuse Large B-cell Lymphoma is an early-stage landscape with 8 programs across 5 companies. The most active players are Roche, Gynecologic Oncology Group, Eastern Cooperative Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 1G

Gynecologic Oncology Group

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 1Gilead logo

Gilead

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

63%

Small molecule

5 of 8 classified programs — the dominant modality here.

38%ALL OTHERSMonoclonal antibody225%Cell therapy113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma
Recruiting·AAIDS Malignancy Consortium·Phase 1·NCT05077527·20 enrolled
A Feasibility Study of Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma
Not yet recruiting·National Cancer Institute (NCI)·Phase 1·NCT07649304·15 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)